Human Genetics

, Volume 108, Issue 5, pp 416–429

Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations

Authors

  •  E. Serra
    • Centre de Genètica Mèdica i Molecular – IRO, Hospital Duran i Reynals, Avia. Castelldefels, Km 2.7, L'Hospitalet de Llobregat, 08907-Barcelona, Spain
  •  E. Ars
    • Centre de Genètica Mèdica i Molecular – IRO, Hospital Duran i Reynals, Avia. Castelldefels, Km 2.7, L'Hospitalet de Llobregat, 08907-Barcelona, Spain
  •  A. Ravella
    • Servei de Dermatologia, Hospital de la Creu Roja, Barcelona, Spain
  •  A. Sánchez
    • Servei de Genètica (AS) and Servei de Dermatologia (SP), Hospital Clínic, Barcelona, Spain
  •  S. Puig
    • Servei de Genètica (AS) and Servei de Dermatologia (SP), Hospital Clínic, Barcelona, Spain
  •  T. Rosenbaum
    • Department of Neuropediatrics, Heinrich Heine University, Children's Hospital, Düsseldorf, Germany
  •  X. Estivill
    • Centre de Genètica Mèdica i Molecular – IRO, Hospital Duran i Reynals, Avia. Castelldefels, Km 2.7, L'Hospitalet de Llobregat, 08907-Barcelona, Spain
  •  C. Lázaro
    • Centre de Genètica Mèdica i Molecular – IRO, Hospital Duran i Reynals, Avia. Castelldefels, Km 2.7, L'Hospitalet de Llobregat, 08907-Barcelona, Spain
Original Investigation

DOI: 10.1007/s004390100514

Cite this article as:
Serra, E., Ars, E., Ravella, A. et al. Hum Genet (2001) 108: 416. doi:10.1007/s004390100514

Abstract.

Neurofibromas, benign tumors that originate from the peripheral nerve sheath, are a hallmark of neurofibromatosis type 1 (NF1). Although loss of heterozygosity (LOH) is a common phenomenon in this neoplasia, it only accounts for part of the somatic NF1 mutations found. Somatic point mutations or the presence of "two hits" in the NF1 gene have only been reported for a few neurofibromas. The large size of the NF1 gene together with the multicellular composition of these tumors has greatly hampered their molecular characterization. Here, we present the somatic NF1 mutational analysis of the whole set of neurofibromas studied by our group and consisting in 126 tumors derived from 32 NF1 patients. We report the identification of 45 independent somatic NF1 mutations, 20 of which are reported for the first time. Different types of point mutations together with LOH affecting the NF1 gene and its surrounding region or extending along the 17q arm have been found. Among point mutations, those affecting the correct splicing of the NF1 gene are common, coinciding with results reported on germline NF1 mutations. In most cases, we have been able to confirm that both copies of the NF1 gene are inactivated. We have also found that both somatic and germline mutations can be expressed at the RNA level in the neoplastic cells. Furthermore, we have observed that the study of more than one tumor derived from the same patient is useful for the identification of the germline mutation. Finally, we have noticed that the culture of neurofibromas and their fibroblast clearance facilitates LOH detection in cases in which it is difficult to determine.

Copyright information

© Springer-Verlag 2001